UPDATE: Aegis Capital Starts Kintara Therapeutics, Inc (KTRA) at Buy

September 14, 2020 11:34 AM EDT
Get Alerts KTRA Hot Sheet
Price: $1.82 +1.68%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 12 | New: 42
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(Updated - September 14, 2020 11:37 AM EDT)

(Updated to add analyst comment)

Aegis Capital analyst Nathan Weinstein initiates coverage on Kintara Therapeutics, Inc (NASDAQ: KTRA) with a Buy rating and a price target of $6.00.

Analyst comments: "Data from trials, along with the results of a planned REM-001 CMBC confirmatory study that will serve as a lead-in to a pivotal study, could catalyze a re-rating of KTRA shares in the market, we believe. We are launching coverage on Kintara Therapeutics (KTRA) with a BUY rating and $6.00 price target predicated on a discounted cash flow valuation that credits revenue from both VAL-083 in GBM and REM-001 in CMBC, and utilizes a 33% PoS (for both oncology assets) and 30% discount rate."

For an analyst ratings summary and ratings history on Kintara Therapeutics, Inc click here. For more ratings news on Kintara Therapeutics, Inc click here.

Shares of Kintara Therapeutics, Inc closed at $1.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage